Increased H1 profits drive Sanitas' expansion plans in Russia
This article was originally published in Scrip
Sanitas, Lithuania's largest pharmaceutical manufacturer, wants to expand in Russia on the back of increased six-month revenues and profits; it hopes that the country's share in its total sales will rise from the current 14% to 20% by the end of this year.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.